Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) and GeoVax Labs (NASDAQ:GOVX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.
Institutional and Insider Ownership
6.1% of GeoVax Labs shares are owned by institutional investors. 1.8% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Artiva Biotherapeutics and GeoVax Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Artiva Biotherapeutics | N/A | -53.86% | -48.16% |
| GeoVax Labs | N/A | -743.64% | -394.74% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Artiva Biotherapeutics | 1 | 4 | 2 | 0 | 2.14 |
| GeoVax Labs | 1 | 1 | 1 | 0 | 2.00 |
Artiva Biotherapeutics presently has a consensus target price of $24.80, indicating a potential upside of 491.89%. GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 88,867.97%. Given GeoVax Labs’ higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Artiva Biotherapeutics.
Volatility & Risk
Artiva Biotherapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.69, suggesting that its stock price is 269% more volatile than the S&P 500.
Valuation and Earnings
This table compares Artiva Biotherapeutics and GeoVax Labs”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Artiva Biotherapeutics | $250,000.00 | 819.40 | -$83.86 million | ($3.30) | -1.27 |
| GeoVax Labs | $2.49 million | 0.50 | -$21.47 million | ($11.34) | -0.01 |
GeoVax Labs has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.
Summary
Artiva Biotherapeutics beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
About GeoVax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
